KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Current Deferred Revenue (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Current Deferred Revenue data on record, last reported at $485.4 million in Q3 2025.

  • For Q3 2025, Current Deferred Revenue rose 282.24% year-over-year to $485.4 million; the TTM value through Sep 2025 reached $485.4 million, up 282.24%, while the annual FY2024 figure was $130.3 million, 158.36% up from the prior year.
  • Current Deferred Revenue reached $485.4 million in Q3 2025 per SRPT's latest filing, up from $395.4 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $485.4 million in Q3 2025 and bottomed at $22.5 million in Q3 2023.
  • Average Current Deferred Revenue over 5 years is $121.9 million, with a median of $89.2 million recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: tumbled 74.79% in 2023, then skyrocketed 464.6% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $89.2 million in 2021, then changed by 0.0% to $89.2 million in 2022, then plummeted by 43.51% to $50.4 million in 2023, then soared by 158.36% to $130.3 million in 2024, then skyrocketed by 272.69% to $485.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $485.4 million in Q3 2025, $395.4 million in Q2 2025, and $44.9 million in Q1 2025.